Nrip1-Edited Adipose Progenitor Cells for Thermogenic Therapy

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for metabolic diseases such as type 2 diabetes and obesity are limited by the scarcity of human beige adipocytes and the challenges of effectively targeting genes like Nrip1 for therapeutic enhancement without off-target effects.

Innovation Solution

The use of RNA-guided nucleases (RGN) and guide RNAs (gRNAs) to disrupt the Nrip1 gene in adipose progenitor cells, inducing differentiation into thermogenic adipocytes with high efficiency and minimal off-target effects, using CRISPR-Cas9 technology and ribonucleoprotein complexes.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional treatments are used for metabolic diseases, then current standard care is provided, but therapeutic effectiveness is limited and new treatments are needed

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidtreatment options

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by modifying the genetic parameters of adipose cells through CRISPR-Cas9 mediated editing of the Nrip1 gene. This genetic parameter modification transforms conventional adipocytes into engineered adipocytes with enhanced thermogenic properties, thereby improving therapeutic effectiveness for metabolic diseases while maintaining treatment versatility through cell-based therapy approaches

Inventive Principle:

Principle #35Parameter changes

2Reliability

If human beige adipocytes are used for therapy, then therapeutic effect is achieved, but scarcity of these cells limits availability

Engineering Contradiction:

Improvetherapeutic effectVSAvoidavailability of beige adipocytes

Core Design Contradiction:

ReliabilityVSQuantity of substance

Solution Approach 1:

The patent extracts and isolates adipose progenitor cells from adult subcutaneous adipose tissue, then differentiates them in vitro into thermogenic adipocytes with engineered Nrip1 disruption. This extraction and reconstitution approach overcomes the scarcity of human beige adipocytes by generating therapeutic cells from readily available progenitor cells, thereby improving both therapeutic effect reliability and cell availability

Inventive Principle:

Principle #2Taking out (Extraction)

3Reliability

If gene targeting is performed to enhance therapeutic effect, then treatment specificity is improved, but off-target effects may occur

Engineering Contradiction:

Improvetreatment specificityVSAvoidoff-target effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by using CRISPR-Cas9 technology with specific guide RNAs targeting the Nrip1 gene in adipose progenitor cells. This localized genetic modification ensures that the therapeutic effect is confined to the intended target gene and cell type, improving treatment specificity while minimizing off-target effects through precise gene targeting and cell-type-specific differentiation protocols

Inventive Principle:

Principle #3Local quality

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enhances glucose tolerance and reduces adiposity and liver triglycerides by upregulating thermogenic genes and secreted factors, demonstrating therapeutic potential in obese mice and humans.

Implementation Method 1

Methodology Applied

Scientific EffectCRISPR-Cas9 gene editing:

Data Source

PatentUS20260049295A1Targeting Nrip1 to Alleviate Metabolic Disease

Publication Date: 2026.02.19 UNIV OF MASSACHUSETTS

AI summary

Provided herein are methods and compositions for disrupting expression of nuclear receptor interacting protein 1 (Nrip1) in adipose cells, and methods of use of such adipose cells for treating, or reducing risk of, a condition associated with an elevated body mass index (BMI).